Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JK 50561

X
Drug Profile

JK 50561

Alternative Names: 50561; Inforget; JK-50561

Latest Information Update: 22 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Joekai Biotechnology
  • Class Antidementias; Behavioural disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Rac1 GTP binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Amnesia; Brain disorders; Vascular dementia

Most Recent Events

  • 22 Aug 2023 Beijing Joekai Biotechnology plans phase-IIa trial in Vascular dementia in 3Q of 2024 (Beijing Joekai Biotechnology pipeline, August 2023)
  • 22 Aug 2023 Beijing Joekai Biotechnology plans phase-III trial in Alzheimer's disease in 4Q of 2024 (Beijing Joekai Biotechnology pipeline, August 2023)
  • 24 Apr 2023 Preclinical trials in Amnesia in China (unspecified route) prior to April 2023 (Beijing Joekai Biotechnology pipeline, April 2023).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top